Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
Investing.com -- Evommune, a clinical-stage biotechnology company, has filed for an initial public offering on the New York Stock Exchange under the ticker symbol "NYSE:EVMN".
The company, which develops therapies targeting chronic inflammatory diseases, has not yet disclosed the number of shares to be offered or the price range for the IPO. Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor will serve as underwriters for the offering.
Evommune focuses on developing treatments for chronic inflammatory conditions including chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company currently has two product candidates in Phase 2 trials: EVO756 and EVO301.
EVO756, the company’s most advanced product candidate, is an oral small molecule antagonist targeting MRGPRX2, a receptor found on mast cells and peripheral sensory neurons. The company completed a Phase 2 trial for chronic inducible urticaria in May 2025, with 70% of observed patients showing improvement after four weeks of treatment. Evommune initiated a Phase 2b trial for chronic spontaneous urticaria in April 2025, with results expected in the first half of 2026. A Phase 2b trial for atopic dermatitis began in August 2025, with results anticipated in the second half of 2026.
EVO301, the company’s second clinical-stage candidate, is a long-acting fusion protein designed to neutralize the IL-18 inflammatory pathway. Evommune secured global rights to develop and commercialize this product from AprilBio in June 2024. A Phase 2 trial for moderate-to-severe atopic dermatitis is underway, with initial data expected in the first half of 2026. The company plans to initiate a Phase 2 trial for ulcerative colitis in 2026.
Evommune has applied for listing on the NYSE and noted that the offering is contingent upon approval of this listing. The company has granted underwriters a 30-day option to purchase additional shares to cover over-allotments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.